These results indicate that oncolysis combined with PD-L1 blockade and IL-12 enhances the potency of adoptively transferred HER2.CARTs to control tumor growth in subcutaneous CAPAN-1 tumors. The gene discussed is ERBB2; the disease is neoplasm.